The dose needed depends on how bad the deficiency is, your age, and your health
Researchers proceeding despite these unknowns must accept that they are operating without the safety data that clinical trials are designed to generate
ODT dosing considerations The ODT formulation uses significantly higher milligram doses because oral bioavailability is much lower than injectable
What you describe isn't quite the same as '0', is it
the BPC peptide salts of the present invention are useful for the treatment of hypertension, angina, impotence, circulatory shock, septic shock, stroke, inflammation, respiratory distress syndromes, pulmonary hypertension, pancreatitis, adhesion and aggregation of platelets and leukocytes, endothelial dysfunction, and Parkinson's disease
And its why the burden often falls on the patient to ask